Compounds > hydrocortisone acetate, (11beta)-isomer
Page last updated: 2024-08-01 21:05:08

hydrocortisone acetate, (11beta)-isomer

Description

Cross-References

ID SourceID
PubMed CID5702068
CHEMBL ID306147
SCHEMBL ID2679809
MeSH IDM0314595

Synonyms (42)

Synonym
gnf-pf-4997 ,
CHEMBL306147
BRD-A65767837-001-02-8
KBIO1_000194
DIVK1C_000194
SPECTRUM_000879
IDI1_000194
BSPBIO_002134
NCGC00178800-01
SPECTRUM5_000826
KBIO2_003927
KBIOSS_001359
KBIOGR_000353
KBIO2_001359
KBIO3_001354
KBIO2_006495
NINDS_000194
SPECTRUM2_001030
SPECTRUM4_000007
SPECTRUM3_000457
SPBIO_001219
SPECTRUM1500338
HMS2091L07
HMS500J16
HMS1920D21
NCGC00183367-01
cas-50-03-3
tox21_113074
dtxcid0028612
dtxsid0048686 ,
pharmakon1600-01500338
nsc-757060
nsc757060
CCG-40248
NCGC00021277-04
tox21_113074_1
SCHEMBL2679809
AB00052014_02
SR-05000001650-1
sr-05000001650
SBI-0051408.P003
BRD-A65767837-001-03-6

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
GALC proteinHomo sapiens (human)Potency0.7079AID1159614
TDP1 proteinHomo sapiens (human)Potency33.4983AID686979
AR proteinHomo sapiens (human)Potency0.1270AID1259243; AID1259247; AID1259381; AID743036; AID743040; AID743042; AID743053; AID743054
progesterone receptorHomo sapiens (human)Potency16.4345AID1346784; AID1346795; AID1347036
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.2016AID720691; AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.0879AID743069; AID743075; AID743078; AID743080; AID743091
GVesicular stomatitis virusPotency17.3768AID1645842
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.1059AID743083
Interferon betaHomo sapiens (human)Potency17.3768AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency17.3768AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency17.3768AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency17.3768AID1645842

Bioassays (66)

Assay IDTitleYearJournalArticle
AID73417Inhibition of human Farnesyltransferase at 100 uM1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
ISSN: 0022-2623		Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490		In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490		In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
ISSN: 0022-2623		Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490		In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490		In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
ISSN: 0022-2623		Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID51053Compound was evaluated for its binding affinity towards the human corticosteroid binding globulin1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
ISSN: 0022-2623		Self-organizing molecular field analysis: a tool for structure-activity studies.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
ISSN: 0022-2623		Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
ISSN: 1464-3405		Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
ISSN: 1872-9096		High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X		Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X		Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
ISSN: 1552-454X		A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
ISSN: 1095-9203		Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (26.32)18.2507
2000's1 (5.26)29.6817
2010's7 (36.84)24.3611
2020's6 (31.58)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
quinacrine
2
acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor		2008201114.5low000110
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
1
non-proteinogenic alpha-amino acid2011201113.0low000010
1,3-dipropyl-8-cyclopentylxanthine
2
oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor		2008201114.5low000110
nsc-267703
1
anthracycline2011201113.0high000010
dactinomycin
1
cyclodepsipeptide2011201113.0medium000010
1-aminoindan-1,5-dicarboxylic acid
2
2008201114.5low000110
amodiaquine
1
aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug		2011201113.0low000010
astemizole
2
benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist		2008201114.5low000110
berberine
1
alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker		2011201113.0low000010
chloroquine
2
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		2008201114.5low000110
aricine
2
cinchona alkaloid2008201114.5medium000110
clofilium
1
benzenes;
organic amino compound		2011201113.0low000010
clotrimazole
2
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic		2008201114.5low000110
dequalinium
1
quinolinium ionantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor		2011201113.0low000010
thiorphan
1
N-acyl-amino acid1997199727.0low001000
nsc-526417
1
2011201113.0medium000010
gentian violet
1
iminium ionantibacterial agent;
antifungal agent		2011201113.0low000010
hexahydrosiladifenidol
1
2011201113.0low000010
mefloquine hydrochloride
2
organofluorine compound;
piperidines;
quinolines;
secondary alcohol		2008201114.5low000110
moclobemide
2
benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic		2008201114.5low000110
n-acetyl-4-nitrophenylserinol
2
2008201114.5high000110
oxiracetam
2
organonitrogen compound;
organooxygen compound		2008201114.5low000110
pentamidine
2
aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic		2008201114.5low000110
pronethalol
2
naphthalenes2008201114.5low000110
propafenone
2
aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug2008201114.5low000110
pyrimethamine
2
aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2008201114.5low000110
scriptaid
2
isoquinolines2008201114.5low000110
trimethoprim
1
aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic		1997199727.0low001000
6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone
2
cyclodepsipeptide2008201114.5high000110
cortisone acetate
1
corticosteroid hormone1998199826.0low001000
corticosterone
3
11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1994199728.0low003000
prednisolone
4
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic		1994199927.2low004000
estriol
3
16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite		1994199728.0low003000
estrone
3
17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite		1994199728.0low003000
androsterone
3
17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone		1994199728.0low003000
etiocholanolone
2
17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid		human metabolite;
mouse metabolite		1994199728.5low002000
androstenedione
3
17-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite		1994199728.0low003000
desoxycorticosterone
3
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1994199728.0low003000
cycloheximide
2
antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor		2008201114.5low000110
17-alpha-hydroxyprogesterone
3
17alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone		human metabolite;
metabolite;
mouse metabolite;
progestin		1994199728.0low003000
phanquinone
2
orthoquinones2008201114.5medium000110
diphenan
2
diarylmethane2008201114.5high000110
2-phenylacetamide
2
monocarboxylic acid amidemouse metabolite2008201114.5medium000110
tetraphenylborate
2
2008201114.5low000110
pregnenolone
3
20-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite		1994199728.0low003000
cycloguanil hydrochloride
2
hydrochloride;
organic molecular entity		2008201114.5medium000110
cycloguanil
1
triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2011201113.0low000010
triphenyltetrazolium
1
organic cation2011201113.0low000010
nandrolone
4
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite1994199927.2low004000
berbamine
1
phenylpropanoid2011201113.0low000010
emetine
2
isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor		2008201114.5low000110
androstenediol
3
17beta-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid		androgen;
human metabolite;
mouse metabolite;
radiation protective agent		1994199728.0low003000
dihydrotestosterone
3
17beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite		1994199728.0low003000
dequalinium chloride
2
organic chloride saltantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor		2008201114.5low000110
gentian violet
1
organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye		2008200816.0low000100
algestone
4
16alpha-hydroxy steroid;
17-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
tertiary alpha-hydroxy ketone		progestin1994199927.2low004000
Berberine chloride (TN)
2
organic molecular entity2008201114.5low000110
9,10-dimethylanthracene
2
2008201114.5low000110
c 137
2
2008201114.5medium000110
palmatine
1
berberine alkaloid;
organic heterotetracyclic compound		plant metabolite2011201113.0low000010
4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine
2
1997201120.0low001010
diaveridine
1
aminopyrimidineantiparasitic agent;
drug allergen		1997199727.0low001000
buquinolate
2
2008201114.5high000110
propranolol glycol
2
2008201114.5high000110
naphthoxybutanolcyclohexylamine
1
2011201113.0low000010
captopril
1
alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1997199727.0low001000
staurosporine
1
indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector		2011201113.0low000010
propamidine
1
aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug		2011201113.0low000010
thionine
1
2008200816.0low000100
neocuproine
2
phenanthrolineschelator;
copper chelator		2008201114.5low000110
mefloquine hydrochloride
1
hydrochloride2008200816.0low000100
toxoflavin
2
carbonyl compound;
pyrimidotriazine		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor		2008201114.5low000110
selfotel
1
non-proteinogenic alpha-amino acid2008200816.0low000100
plasmenylserine
2
O-phosphoserineEC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor;
EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2008201114.5low000110
quinocide
1
2011201113.0low000010
2,2',2''-terpyridine
2
terpyridineschelator2008201114.5low000110
clobetasone butyrate
1
organic molecular entity2011201113.0low000010
cletoquine
2
2008201114.5medium000110
jatrorrhizine
1
alkaloid2011201113.0low000010
lycorine
2
indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor		2008201114.5low000110
bathophenanthroline
2
benzenes;
phenanthrolines		chelator2008201114.5low000110
fascaplysine
1
2008200816.0low000100
LSM-4272
1
beta-carbolines2011201113.0low000010
tryptanthrine
2
alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound		2008201114.5low000110
2,4-diamino-5-benzylpyrimidine
1
1997199727.0low001000
ethylhydrocupreine
2
aromatic ether;
cinchona alkaloid		EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor2008201114.5low000110
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine
2
1997201120.0medium001010
cinchonine
2
(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite2008201114.5low000110
17-alpha-hydroxypregnenolone
3
17alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid;
hydroxypregnenolone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1994199728.0low003000
11-ketoprogesterone
4
corticosteroid hormone1994199927.2medium004000
7-chloro-4-aminoquinoline
2
aminoquinoline2008201114.5low000110
mmv665852
2
2008201114.5medium000110
1,3,4,10-Tetrahydro-9(2H)-acridinone
2
acridines2008201114.5medium000110
wr 158122
2
2008201114.5medium000110
10-deazaaminopterin
1
2011201113.0low000010
2 alpha-methyl-9 alpha-fluorocortisol
4
1994199927.2high004000
dihydroergocristine
2
ergot alkaloidadrenergic antagonist;
vasodilator agent		2008201114.5low000110
benzamil
1
guanidines;
pyrazines		2011201113.0low000010
3',4'-dichlorobenzamil
2
guanidines;
pyrazines		2008201114.5low000110
cleistanthin b
2
beta-D-glucoside;
cleistanthins;
monosaccharide derivative		alpha-adrenergic antagonist;
antihypertensive agent;
diuretic		2008201114.5medium000110
n-acetyltyramine
2
acetamides;
tyramines		animal metabolite;
Aspergillus metabolite;
bacterial metabolite;
marine metabolite;
quorum sensing inhibitor		2008201114.5low000110
1,3-di(4-imidazolinophenoxyl)propane
2
2008201114.5medium000110
7h-pyrido(4,3-c)carbazole
2
2008201114.5high000110
imiloxan
1
benzodioxine2011201113.0low000010
cl 246738
2
2008201114.5medium000110
retrothiorphan
1
1997199727.0low001000
a 58365a
1
1997199727.0medium001000
celastrol methyl ester
2
carboxylic ester2008201114.5low000110
epiberberine
1
2011201113.0low000010
2-phenyl-4-oxohydroquinoline
2
2008201114.5low000110
cypripedin
2
phenanthrol2008201114.5high000110
respinomycin d
2
2008201114.5high000110
azacrin
1
2008200816.0medium000100
cortisone
3
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1994199728.0low003000
acetoxycycloheximide
2
2008201114.5medium000110
(R)-Roemerine
2
isoquinoline alkaloid2008201114.5medium000110
5 alpha-androstane-3 beta,17 beta-diol
3
17beta-hydroxy steroid;
3beta-hydroxy steroid;
androstane-3,17-diol		Daphnia magna metabolite;
human metabolite		1994199728.0high003000
anisomycin
1
monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor		2008200816.0low000100
2-guanidine-4-methylquinazoline
2
2008201114.5low000110
jatrorrhizine chloride
1
2008200816.0medium000100
mensacarcin
1
2011201113.0medium000010
puromycin
2
puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor		2008201114.5low000110
cortodoxone
3
deoxycortisol;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1994199728.0low003000
quinidine
2
cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker		2008201114.5low000110
cephaelin
1
pyridoisoquinoline2011201113.0low000010
trichostatin a
1
antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector		2008200816.0low000100
epothilone b
2
epothilone;
epoxide		antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent		2008201114.5low000110
wr-142,490
1
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial2011201113.0medium000010
dactinomycin
2
actinomycinmutagen2008201114.5low000110
1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
2
pyrimidotriazine2008201114.5medium000110
jp-1302
2
2008201114.5low000110
7-hydroxy-2-methoxy-1,4-phenanthrenedione
2
2008201114.5high000110
cgp 60474
2
substituted aniline2008201114.5medium000110
prednisolone hemisuccinate
1
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
hemisuccinate;
tertiary alpha-hydroxy ketone		anti-inflammatory drug1998199826.0low001000
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol
1
alkylbenzene2011201113.0low000010
2-[2-hydroxy-6,7-dimethoxy-4-(4-morpholinyl)-1-naphthalenyl]-N-phenylacetamide
2
naphthols2008201114.5high000110
N4-(3-chlorophenyl)-6-methyl-N2-(phenylmethyl)pyrimidine-2,4-diamine
2
aralkylamine2008201114.5high000110
n-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine
1
2011201113.0high000010
2,6-bis(benzimidazol-2-yl)pyridine
2
benzimidazoles2008201114.5low000110
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine
2
2008201114.5medium000110
N-[4-(1-azepanyl)phenyl]-2-chloroacetamide
2
anilide2008201114.5high000110
N-(4-methylphenyl)carbamic acid (cyclopentylideneamino) ester
2
toluenes2008201114.5high000110
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine)
2
benzimidazoles2008201114.5medium000110
1,4,8-trimethyl-12-quinolino[2,3-b]quinolinamine
2
aminoquinoline2008201114.5high000110
2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone
2
aromatic amide;
heteroarene		2008201114.5high000110
1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone
2
quinolines2008201114.5high000110
stk295900
2
2008201114.5high000110
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole
2
benzimidazoles2008201114.5high000110
N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine
2
aromatic ether2008201114.5high000110
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline
2
benzimidazoles2008201114.5high000110
4-(1-adamantyl)-2-methyl-1,3-thiazole
2
thiazoles2008201114.5high000110
2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile
2
piperazines;
pyridines		2008201114.5high000110
1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea
2
pyrazoles;
ring assembly		2008201114.5high000110
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine
2
quinazolines2008201114.5high000110
polysulfide rubber
2
2008201114.5high000110
lch-7749944
1
2011201113.0medium000010
4-(4-nitrophenyl)-N-prop-2-enyl-1-piperazinecarbothioamide
2
piperazines2008201114.5high000110
zd 6474
2
aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor		2008201114.5low000110
5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamide
2
indoles2008201114.5high000110
N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide
2
aromatic amide;
heteroarene		2008201114.5high000110
2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide
2
organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound		2008201114.5high000110
trichomonacid
2
2008201114.5high000110
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
2
triazolopyrimidines2008201114.5medium000110
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethyl)-3-oxo-1H-isoindole-4-carboxamide
2
isoindoles2008201114.5high000110
cgp 71683 a
1
naphthalenes;
sulfonic acid derivative		2011201113.0medium000010
2-(dimethylaminostyryl)-1-ethylpyridinium
1
pyridinium ion2011201113.0low000010
enalaprilat anhydrous
1
dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1997199727.0low001000
penicillin v
1
1,1'-diethyl-2,2'-cyanine;
quinolines		2008200816.0medium000100
xib 4035
2
2008201114.5medium000110
10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one
2
pyridochromene2008201114.5high000110
lumefantrine
2
fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial2008201114.5low000110
suloctidil
1
2008200816.0low000100
edatrexate
2
glutamic acid derivative2008201114.5low000110
clavaric acid
1
1998199826.0medium001000
cgp 71683 a
1
2008200816.0low000100
16-methylprogesterone, (16alpha)-isomer
2
1997199926.0high002000
norketotifen
1
organosulfur heterocyclic compound2011201113.0high000010
artenimol
1
2008200816.0low000100
aee 788
2
6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug		2008201114.5low000110
tomaymycin
2
tomaymycin2008201114.5low000110
amodiaquine hydrochloride
1
2008200816.0low000100
gramicidin a
2
2008201114.5low000110
N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide
2
benzenes2008201114.5high000110
rs 39604
1
hydrochlorideserotonergic antagonist2008200816.0low000100
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea
2
quinazolines2008201114.5high000110
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Anemia, Fanconi0
1
201620168.0low000010
Congenital Zika Syndrome0
1
202020204.0low000010
Disease Models, Animal0
1
202020204.0low000010
Encephalitis, Polio0
1
2011201113.0low000010
Fanconi Anemia0
1
201620168.0low000010
Infections, Plasmodium0
2
2008201114.5medium000110
Malaria0
2
2008201114.5medium000110
Poliomyelitis0
1
2011201113.0low000010
Zika Virus Infection0
1
202020204.0low000010

Bioavailability (3)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46		2019
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061		2011